Ebola virus disease poses a global health threat. Here, two studies by Wec et al. and Zhao et al. identified vulnerability in an internal fusion loop of an ebolavirus glycoprotein. Monoclonal antibodies elicited from immunization and isolated from a human survivor that recognized epitopes in this area neutralized all five ebolaviruses, guiding the development of a pan-ebolavirus immunotherapy.
The genus ebolavirus currently includes five species: Zaire ebolavirus (EBOV), Sudan ebolavirus (SUDV), Bundibugyo ebolavirus (BDBV), Taï Forest ebolavirus (TAFV), and Reston ebolavirus (RESTV). The first three cause ebolavirus diseases (EVD) that present with characteristic symptoms, including viral hemorrhagic fever, in humans and are associated with a high case fatality rate. Ebolaviruses have caused 24 epidemics in Africa since they were first identified in 1976 in Zaire and Sudan, with the largest epidemic to date being the 2013-2016 outbreak in West Africa-particularly Liberia, Guinea, and Sierra Leone. During the outbreak, ZMapp, a cocktail of three monoclonal antibodies (mAbs) specific for the base and glycan cap of EBOV glycoprotein (GP), was provided as humanitarian treatment to Ebola patients, since there were and still are no regulatory approved therapies for EVD. However, a randomized, controlled trial of ZMapp for the treatment of EVD showed that ZMapp was not statistically significantly more efficacious than the standard of care alone (Group et al., 2016) . While several other monoclonal antibodies against GP have been reported, including the mouse monoclonal antibody 6D6 with pan-ebolaviruses neutralizing activity in vitro and protective effect in mice challenged with EBOV and SUDV (Furuyama et al., 2016) , human monoclonal antibodies with in vivo pan-ebolavirus protective effects are still lacking. In this issue, Wec et al. (2017) and Zhao et al. (2017) obtained broadly protective monoclonal antibodies from a human survivor and through immunization, respectively, making a significant breakthrough for developing effective pan-ebolavirus vaccine and immunotherapy.
Ebolavirus glycoprotein (GP) on the virion surface mediates virus entry and is the primary target for immunotherapy and vaccine development. GP is expressed as GP0 and then undergoes post-translational proteolytic cleavage to produce disulfide-linked GP1 and GP2. GP1 is structurally subdivided into the base, glycan cap, head, and mucin-like domain ( Figure 1A ) (Lee and Saphire, 2009 ). The head region possesses a site for binding to virus endosomal receptor Niemann-Pick C1 (NPC1). Since the receptor-binding site within the head is hidden by the glycan cap and mucin-like domain, GP is remodeled to a receptorbinding mode (GP CL ) by enzymatic removal of the glycan cap and mucinlike domain by cysteine cathepsins (Cathepsin L and B) in the late endosome after virion uptake by cellular micropinocytosis. GP2 is responsible for viral-host membrane fusion and contains an internal fusion loop, two heptad repeat regions connected by a linker containing a CX 6 CC motif, the membrane-proximal external region (MPER), a transmembrane domain, and a cytoplasmic domain ( Figure 1A ) (Lee and Saphire, 2009 ). While there have been antibodies discovered with some level of cross-species activity against ebolaviruses, it has not been clear which domains in the viral protein would be most effective in eliciting in vivo panebolavirus neutralizing responses. Here, studies from Wec et al. (2017) and Zhao et al. (2017) highlighted the promise of specific regions in the internal fusion loop of GP2 as a target for this purpose. Wec et al. (2017) screened 349 human mAbs isolated from a survivor of the 2013-2016 EBOV outbreak and found several broadly neutralizing antibodies. They chose two mAbs, ADI-15742 and ADI-15878-which are clonal siblings that neutralized all five ebolaviruses-for in-depth analysis ( Figure 1B) . Zhao et al. (2017) used memory B cells isolated from a cynomolgus macaque immunized with recombinant EBOV-, SUDV-, and BDBV-GPs to look for cross-neutralizing antibodies and identified CA45, which neutralized four of the five ebolaviruses ( Figure 1B ). CA45 inhibited both GP cleavage by cathepsins and the membrane fusion step by targeting the GP base and the root of the GP2 internal fusion loop (Zhao et al., 2017) . In contrast, ADI-15742/ADI-15878 inhibited only the membrane fusion step by arresting GP CL conformational changes through binding to the conserved discontinuous sequences of GP1 and GP2 that span neighboring protomers, including the tip of the GP2 internal fusion loop . Monotherapy with ADI-15742 or ADI-15878 and combination therapy of CA45 with an anti-receptor binding site antibody FVM04 (Keck et al., 2015) showed protective efficacy in mice against infection with the three ebolaviruses (EBOV, SUDV, and BDBV) that are lethal to humans. While these are promising results, it is important to demonstrate the therapeutic efficacy of these mAbs in nonhuman primates before initiating clinical trials in humans.
While these and earlier works demonstrate that the GP2 internal fusion loop is a promising target for the production of pan-ebolavirus neutralizing antibodies, it is worth noting that not every region within the loop is equally effective in terms of eliciting broadly neutralizing response (Keck et al., 2015; Misasi et al., 2016) . Therefore, it is important to understand the structural and molecular basis for the activity of ADI-15742/ADI-15878/CA45. In addition, to develop pan-ebolavirus vaccines that target the GP2 internal fusion loop, the low frequency of memory B cells encoding such antibodies needs to be improved, even though only a few somatic mutations are required for the broad neutralization activity of ADI-15742/ADI-15878.
To establish a standard immunotherapy using monoclonal antibodies against EVD, a cocktail approach is required for effective control of EVD in nonhuman primates. An obvious approach would be to select cocktail components from multiple monoclonal antibodies against GPs, in particular pairing mAbs that do not complete with each other for binding to GP-for instance, a highly potent neutralizing mAb that targets the GP2 internal fusion loop and a highly potent neutralizing mAb that recognizes the receptor-binding site of GP1. Interestingly, recent studies have shown a protective effect using combinatory approaches with two non-protective antibodies, or a ''Trojan horse'' strategy, to deliver an antibody that directly targets endosomal compartments with broadly reactive but non-neutralizing anti-GP Fab Wec et al., 2016) . While there may be multiple rationales for designing combinatory therapy, they have one critical issue in common: the emergence of antigenic escape mutants upon treatment in patients. Considering the extensive human-to-human transmission of these viruses, as exemplified by the recent outbreak, the likelihood of emergence of antigenic escape mutants should be considered as a criterion guiding the design of antibody cocktail regimens.
Even with the best possible antibody cocktail, there would likely be viruses that were not optimally combatted or patients with suboptimal outcomes. It is therefore important to continue to develop other means for controlling ebolavirus infection, including small molecule compounds and vaccines (De Clercq, 2015) .
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Figure 1. Cross-Reactive mAbs and Their Epitopes on Ebolavirus GP
(A) Epitopes on the structure of ebolavirus GP. The ebolavirus GP trimer (PDB: 5JQ3) is composed of three heterodimers each of GP1 (blue) and GP2 (light blue). The base, glycan cap (deep blue), head (which includes the receptor-binging site), and mucin-like domain (not shown in the 3D structure) of GP1 and the internal fusion loop, HR1, and HR2 of GP2 are mapped on the structure. The target sites of the reported cross-reactive mAbs are mapped on the GP structure. Critical contact sites or amino-acid changes found in escape mutants for ADI-15750, ADI-15968, BDBV289, BDBV43, BDBV324, and BDBV370 are shown in yellow (G271, W275, Y241, and L273). Amino-acid changes found in escape mutants for ADI-15946 (K510, orange), 6D6 (G528 and A530, pink), ADI-15878, and ADI15742 (G528, pink) are also highlighted. Critical contacts for CA45 include R64, Y517, G546, and N550 (green). ADI-16061 and BDBV223 bind to HR2. ADI-16061 is evaded by mutations in H628 and D632 (yellow; D632 position estimated). There are no known escape mutants for BDBV223. These Classifying sensory experiences as either novel or familiar represents a fundamental challenge to neural processing. In this issue of Cell, Hattori et al. describe a circuit mechanism by which a novel stimulus that initially interests a fruit fly turns into a familiar one.
In Aesop's Fables, interactions between a lowly fox and a kingly lion begin with appropriate fear and deference but recede toward casual indifference through repeated encounters. How does the brain categorize a sensory stimulus as familiar or novel, and how does the latter become the former through experience? In this issue of Cell, Hattori et al. (2017) describe a circuit mechanism by which a novel stimulus that initially interests a fruit fly turns into a familiar one that elicits only indifference.
The sensory world is an ever-changing mix of signals that, if properly interpreted, can reward particular behaviors. Animals can form associative memories that link specific sensory inputs with salient events through the simultaneous activation of sensory neurons and facilitating modulatory input. In both mammals and fruit flies, salience is signaled by the release of dopamine, changing synaptic strength so as to couple either attractive or aversive behavioral responses to the coincident stimulus (Bromberg-Martin et al., 2010; Quinn et al., 1974; Waddell, 2010) . At the same time, the absence of a salient, memory-forming event does not preclude an animal from responding differently to novel versus familiar stimuli. For example, the Aplysia gill withdrawal reflex will adapt to repeated mechanical stimulation by suppressing initially strong responses (Pinsker et al., 1970) . While both of these mechanisms can alter an animal's behavioral response to familiar stimuli, another reasonable strategy would be to evaluate the novelty of every stimulus, even in the absence of a strongly salient event, so as to be alerted to potentially useful new information. Intriguingly, in mammals, subsets of dopaminergic neurons fire bursts in the presence of a new or startling stimulus, but not a familiar one (BrombergMartin et al., 2010; Schultz et al., 1993) . However, direct evidence for circuit modulation during the transition from novel to familiar has not previously been observed. Using a combination of behavior, genetic manipulations, and calcium imaging, Hattori et al. (2017) discover not only a dopaminergic neuron that responds strongly to novel stimuli, but also the circuit mechanism by which this neuron suppresses responses to familiar odors in the fruit fly.
The Drosophila olfactory system has long provided insights into the logic of both sensory processing and memory. Odors activate a subset of olfactory sensory neurons, each of which synapse upon specific projection neurons. These, in turn, make synaptic connections in a pair of brain structures called the mushroom bodies, where each projection neuron makes synaptic connections with a different subset of Kenyon cells, creating a neural substrate for learning (Figure 1) (Caron et al., 2013; Turner et al., 2008) . Different subsets of dopaminergic neurons innervating the mushroom bodies respond to negative and positive stimuli, such as an electric shock or a sugar reward, and relay these signals to segregated compartments in the mushroom body (Aso et al., 2014) . These signals shape downstream neurons in an olfactory learning paradigm by the concurrent activation of Kenyon cells to odor, a conditioned stimulus (CS), and dopaminergic neurons to the reward or punishment, defining the unconditioned stimulus (US) (Waddell, 2010) . As a result, synaptic output from the mushroom body can be modified
